The Space-X 19 was launched at 12:29 EST on 5th December last; on-board it carries some scientific experiments that will be undertaken on the International Space Station during the Beyond Mission, led by the Italian astronaut Luca Parmitano from the European Space Agency.
The XENOGRISS experiment is financed and managed by the Italian Space Agency and studies the growth and regeneration of biological tissue, using Xenopus laevis tadpoles as the experimental model. The tadpoles’ diet in space is also being examined.
The PI of the experiment is Angela Maria Rizzo from the Department of Pharmacological and Biomolecular Sciences at the University of Milan; her Co-PI is Monica Monici from ASAcampus, the Joint Laboratory between ASA’s Research Division and the Experimental and Clinical Biomedical Sciences Department of the University of Florence.
In addition to its scientific purpose, the experiment also has an important educational purpose: it has been selected within the framework of the YiSS – Youth ISS Science 2019 Competition by the Italian Space Agency, whose objective is to encourage collaboration between Universities and upper secondary schools on topics concerning space research. Taking part in the experiment is a group of students from I.T.I.S. Meucci in Florence, who, led by their teachers Cartocci Stefano, Alessandro Fortuna and Cristina Meringolo, contributed to implementing the trial under the supervision of Kayser Italia, the company responsible for the hardware.
The results of this experiment will help to understand the role of gravity in growth and regeneration processes, providing information which could be useful both from the point of view of future interplanetary space missions and as concerns the analysis of biomedical issues on earth.
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.